Literature DB >> 11031208

c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury.

C Kupatt1, H Habazettl, P Hanusch, R Wichels, D Hahnel, B F Becker, P Boekstegers.   

Abstract

Reperfusion injury after coronary occlusion is in part mediated by leukocyte activation and adhesion. Platelets may interact with polymorphonuclear granulocytes (PMNs), causing aggravated reperfusion injury. We studied whether c7E3Fab, a chimeric Fab fragment blocking platelet glycoprotein (GP) IIb/IIIa, decreases PMN-platelet-dependent myocardial dysfunction after ischemia. Isolated guinea pig hearts (n=5 per group) perfused at a constant flow of 5 mL/min were subjected to ischemia (15 minutes, 37 degrees C) and reperfusion. Human PMNs (10x10(6) cells, 3 mL), platelets (400x10(6), 3 mL), and fibrinogen (1 mg/mL) were infused for 3 minutes after 2 minutes of reperfusion, with or without c7E3Fab. Flow cytometry detected GPIIb/IIIa (platelets) and MAC-1 (aMbeta2, PMNs) as well as coaggregates of both in the effluent, whereas double-fluorescence microscopy visualized intracoronary PMN-platelet coaggregates. Postischemic recovery of pressure-volume work (12-cm H(2)O preload and 60-mm Hg afterload) was defined as the ratio of postischemic to preischemic external heart work (mean+/-SEM). c7E3Fab reduced platelet GPIIb/IIIa detection to 10% of controls, blocked a transcoronary MAC-1 increase (+25% without versus -23% with c7E3Fab), and inhibited PMN-platelet coaggregation in the effluent (49+/-12% without versus 17+/-2% with c7E3Fab) as well as in the hearts themselves (5.0+/-0.7/cm(2) without versus 1.2+/-0.3/cm(2) surface area with c7E3Fab). Postischemic recovery of external heart work (83+/-5% in cell-free hearts) declined to 46+/-4% after postischemic PMN-platelet infusion, but not in the presence of c7E3Fab (74+/-11%) or LPM19c (71+/-6%). We conclude that c7E3Fab inhibits formation of PMN-platelet aggregates during myocardial reperfusion, an effect that protects against PMN-platelet-dependent stunning.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031208     DOI: 10.1161/01.atv.20.10.2226

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Micronized purified flavonoid fraction in pretreating CABG patients.

Authors:  Mustafa Sirlak; A Ruchan Akar; Sadik Eryilmaz; Elif Kuzgun Cetinkanat; Evren Ozcinar; Bulent Kaya; Atilla Halil Elhan; Umit Ozyurda
Journal:  Tex Heart Inst J       Date:  2010

Review 2.  Rationale for intracoronary administration of abciximab.

Authors:  Enrico Romagnoli; Francesco Burzotta; Carlo Trani; Giuseppe G L Biondi-Zoccai; Floriana Giannico; Filippo Crea
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

3.  Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy).

Authors:  Paul A Gurbel; Brian Galbut; Kevin P Bliden; Raymond D Bahr; Matthew T Roe; Victor L Serebruany; W Brian Gibler; Robert H Christenson; E Magnus Ohman
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

4.  Combined Antiplatelet Therapy Reduces the Proinflammatory Properties of Activated Platelets.

Authors:  Alexandra C A Heinzmann; Daniëlle M Coenen; Tanja Vajen; Judith M E M Cosemans; Rory R Koenen
Journal:  TH Open       Date:  2021-10-28

5.  Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration.

Authors:  Youlan L Gu; Marieke L Fokkema; Marthe A Kampinga; Bart J G L de Smet; Eng S Tan; Ad F M van den Heuvel; Felix Zijlstra
Journal:  Trials       Date:  2009-09-28       Impact factor: 2.279

6.  Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis.

Authors:  Tanja Vajen; Rory R Koenen; Isabella Werner; Mareike Staudt; Delia Projahn; Adelina Curaj; Tolga Taha Sönmez; Sakine Simsekyilmaz; David Schumacher; Julia Möllmann; Tilman M Hackeng; Philipp von Hundelshausen; Christian Weber; Elisa A Liehn
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

Review 7.  Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective.

Authors:  Murat Sezer; Niels van Royen; Berrin Umman; Zehra Bugra; Heerajnarain Bulluck; Derek J Hausenloy; Sabahattin Umman
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.